Trexquant Investment LP Buys Shares of 5,387 Pro-Dex, Inc. (NASDAQ:PDEX)

Trexquant Investment LP acquired a new stake in Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,387 shares of the medical instruments supplier's stock, valued at approximately $252,000. Trexquant Investment LP owned 0.17% of Pro-Dex at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of PDEX. FMR LLC grew its stake in shares of Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock valued at $119,000 after buying an additional 1,028 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Pro-Dex in the fourth quarter valued at approximately $202,000. Arrowstreet Capital Limited Partnership acquired a new stake in Pro-Dex in the fourth quarter valued at approximately $255,000. American Century Companies Inc. purchased a new stake in shares of Pro-Dex during the fourth quarter valued at approximately $558,000. Finally, Ritholtz Wealth Management acquired a new position in shares of Pro-Dex during the fourth quarter worth $572,000. Institutional investors and hedge funds own 15.28% of the company's stock.

Pro-Dex Stock Down 0.8 %

NASDAQ PDEX traded down $0.50 during mid-day trading on Friday, reaching $60.83. 31,110 shares of the company's stock traded hands, compared to its average volume of 24,786. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. Pro-Dex, Inc. has a 1-year low of $16.84 and a 1-year high of $65.87. The company has a fifty day simple moving average of $46.39 and a 200-day simple moving average of $43.29. The company has a market cap of $198.37 million, a price-to-earnings ratio of 30.26 and a beta of 0.40.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, equities research analysts expect that Pro-Dex, Inc. will post 2 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Pro-Dex from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th.

Insider Transactions at Pro-Dex

In other news, Director Raymond E. Cabillot sold 842 shares of the business's stock in a transaction that occurred on Friday, March 28th. The stock was sold at an average price of $50.00, for a total value of $42,100.00. Following the completion of the sale, the director now directly owns 278,945 shares in the company, valued at approximately $13,947,250. The trade was a 0.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders sold 35,630 shares of company stock valued at $1,653,248. Insiders own 47.50% of the company's stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.